A retrospective study reported a 0.1% aspiration rate in adults taking GLP-1 receptor agonists and undergoing esophagogastroduodenoscopy, despite a 9.4% rate of retained gastric contents.
Encountering retained gastric contents during esophagogastroduodenoscopy is more common in patients taking glucagon-like peptide 1 receptor agonists but rarely leads to procedure abortion or aspiration, new data from the Cleveland Clinic showed. Currently, recommendations on how to handle EGD in patients taking GLP-1 RAs for type 2 diabetes or obesity vary, due largely to a lack of outcomes data from which to draw evidence-based conclusions.
Data were extracted using a combination of diagnosis codes, procedure codes, and natural language processing and refined by manual chart review. Endoscopy was aborted in 30 cases ; 29 had retained gastric contents. Many also required repeat EGD.
Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Aspiration Pregnancy Pregnant Endoscopy GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists Esophagogastroduodenoscopy Receptors Biliary Disease Gallbladder Disease Obesity Obese Pain Management Abdominal Pain Bariatric Surgery Obesity Surgery Weight Loss Surgery Asthma Asthmatic
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GLP-1s May Increase Post-Endoscopy Aspiration Pneumonia RiskAlthough the overall incidence remains low, patients on GLP-1s have a 33% higher chance of aspiration pneumonia after endoscopic procedures, according to a new large population-based study.
Read more »
Risk On, Risk Off, or Risk Who Knows?Stocks Analysis by Michele Schneider covering: iShares iBoxx $ High Yield Corporate Bond ETF. Read Michele Schneider's latest article on Investing.com
Read more »
Study Finds No Evidence of Thyroid Cancer Risk from GLP-1 AnaloguesA Swedish study of over 435,000 people has found no evidence to support concerns that long-term use of GLP-1 analogues, such as Wegovy and Ozempic, increases the risk of thyroid cancer.
Read more »
GLP-1s Like Ozempic, Wegovy Don’t Substantially Increase Thyroid Cancer Risk, Study SuggestsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Read more »
GLP-1s Like Ozempic, Wegovy Don’t Substantially Increase Thyroid Cancer Risk, Study SuggestsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Read more »
EU Investigation Finds No Link Between GLP-1 Drugs and Suicide RiskHealth regulators in the European Union have concluded a nine-month investigation and found no evidence of a causative link between GLP-1 drugs and an increased risk of suicide or suicidal ideation. This should provide reassurance for individuals taking drugs like Ozempic to treat type 2 diabetes and/or obesity.
Read more »